Zhang J, et al. - This study was attempted to correlate the therapeutic approaches for Wilson’s diseases (WD) patients with neurological symptoms receiving either combined sodium 2, 3-dimercapto-1-propane sulfonate (DMPS), and zinc treatment or D-penicillamine (DPA) monotherapy as first-line therapy, and distinguish the more effective therapeutic approach. Researchers retrospectively examined case records of 158 patients diagnosed with neurological WD. The Global Assessment Scale and Barthel index were applied to assess the neurological symptoms of the patients during the period of treatment. The data displayed that, for the treatment of neurological symptoms of WD, the combined therapeutic method of DPMS and zinc may be a preferred first-line therapy, compared with the treatment with DPA.